Predicting cancer therapy-induced cardiotoxicity: The role of troponins and other markers

Drug Safety

Volumn 25, Issue 5, 2002, Pages 301-311

  Sparano, Joseph A ^a   Brown, David L ^b   Wolff, Antonio C ^c  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BIOCHEMICAL MARKER; CYCLOPHOSPHAMIDE; DOXORUBICIN; MYOSIN ANTIBODY IN 111; NATRIURETIC FACTOR; TRASTUZUMAB; TROPONIN;

CANCER THERAPY; CARDIOTOXICITY; DIAGNOSTIC VALUE; ECHOCARDIOGRAPHY; GATED IMAGING; HEALTH CARE COST; HEART MUSCLE BIOPSY; HEART MUSCLE ISCHEMIA; HEART SCINTISCANNING; HIGH RISK POPULATION; HUMAN; NUCLEAR MEDICINE; PRIORITY JOURNAL; REVIEW;

EID: 0036285309     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200225050-00001     Document Type: Review

References (86)

1. Polychemotherapy for early breast cancer: An overview of the randomised trials
2. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer
3. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-Year follow-up results of French Adjuvant Study Group 05 randomized trial
4. Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens
5. Cytotoxic and hormonal treatment of metastatic breast cancer: A systematic review of published randomized trials involving 31 510 women
6. The role of iron in doxorubicin-induced cardiomyopathy
7. Anthracycline-induced cardiotoxicity
8. Anthracycline cardiomyopathy monitored by morphologic changes
9. Enzymatic defences of the mouse heart against reactive oxygen metabolites: Alterations produced by doxorubicin
10. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations
11. Risk factors for doxorubicin-induced congestive heart failure
12. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity
13. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer
14. Cardiac toxicity 4 to 20 years after completing anthracycline therapy
15. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation
16. Humanization of an anti-p185HER2 antibody for human cancer therapy
17. Basic science of HER-2/neu: A review
18. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor
19. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer
20. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
21. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
22. Cardiac toxicity of trastuzumab (herceptin): Implications for the design of adjuvant trials
23. Cardiac dysfunction in the trastuzumab clinical trials experience
24. Outcome of clinical congestive heart failure induced by anthracycline chemotherapy
25. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ERbB2 and ErbB4 expression in neonatal and adult ventricular myocytes
26. Involvement of the neuregulins and their receptors in cardiac and neural development
27. ErbB3 is required for normal cerebellar and cardiac development: A comparison with ErbB2- and heregulin-deficient mice
28. Neuregulin signaling in the heart. Dynamic targeting of erbB4 to caveolar microdomains in cardiac myocytes
29. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity
30. Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer
31. Indium-111-antimyosin scintigraphy in the early detection of heart damage after anthracycline therapy in children
32. Assessment of anthracycline cardiomyopathy by endomyocardial biopsy
33. Anthracycline cardiomyopathy monitored by morphologic changes
34. Endomyocardial biopsy to monitor anthracycline therapy in children
35. The regulation of contractile activity in muscle
36. New serum markers for acute myocardial infarction
37. Implications of troponin testing in clinical medicine
38. Influence of reperfusion on serum concentrations of cytosolic creatine kinase and structural myosin light chains in acute myocardial infarction
39. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction
40. Comparable detection of acute myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I
41. Meta-analysis in clinical chemistry: Validation of troponin T as a marker for ischemic heart disease
42. Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to infarction and/or sudden death: Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion
43. Intramyocardial platelet aggregation in patients with unstable angina suffering ischemic cardiac death
44. Myocardial infarction redefined: A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction
45. Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies
46. Cardiac troponin I as a predictor of major cardiac events in emergency department patients with acute chest pain
47. Usefulness of cardiac troponin I inpatients undergoing open heart surgery
48. Minor myocardial injury after elective uncomplicated successful PTCA with or without stenting: Detection by cardiac troponins
49. Effects of implantable cardioverter defibrillator implantation and shock application on biochemical markers of myocardial damage
50. Detection of myocardial injury during radiofrequency catheter ablation by measuring cardiac troponin I levels: Procedural correlates
51. Clinically significant blunt cardiac trauma: Role of serum troponin levels combined with electrocardiographic findings
52. Cardiac troponins in congestive heart failure
53. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction
54. Cardiac troponin T in patients with clinically suspected myocarditis
55. Elevated serum concentrations of cardiac troponin in acute allograft rejection after human heart transplantation
56. Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock
57. Cardiac natriuretic peptides - Hope or hype?
58. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction
59. Cardiac troponin I and N-terminal pro-brain natriuretic peptide in relation to fetal heart rate abnormalities during labor
60. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction
61. Cardiac natriuretic peptides: New laboratory parameters in heart failure patients
62. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction
63. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population
64. Rapid assay of plasma brain natriuretic peptide in the assessment of acute dyspnoea
65. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care
66. Neurohumoral prediction of benefit from carvedilol in ischaemic left ventricular dysfunction
67. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischaemic left ventricular dysfunction
68. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricu]ar dysfunction
69. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity
70. Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy
71. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury
72. Elevated serum cardiac troponin-T as a marker for active cardiac injury during therapy for childhood acute lymphoblastic leukemia (ALL)
73. Serum cardiac troponin T levels during treatment of early-stage breast cancer
74. Serum troponin T as an indicator of anthracycline cardiotoxicity in adults
75. A pilot study of troponin T as a prognostic marker in patients treated with 5-flurouracil
76. Cardiac troponin I in pediatrics: Normal values and potential use in the assessment of cardiac injury
77. Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study
78. The value of troponin-I measurement in assessment of anthracycline induced cardiotoxicity among breast cancer patients
79. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
80. Assessment of cardiotoxicity of high dose cyclophosphamide with electrocardiographic, echocardiographic, and troponin I monitoring in patients with breast tumors
81. Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients
82. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma
83. Elevated B-type natriuretic peptide levels after anthracycline administration
84. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity
85. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer
86. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin